110年 - 110 國立臺灣大學_碩士班招生考試_藥學研究所、臨床藥學研究所:生物藥劑學#100395

科目：研究所、轉學考(插大)◆生物藥劑學 | 年份：110年 | 選擇題數：0 | 申論題數：14

試卷資訊

所屬科目：研究所、轉學考(插大)◆生物藥劑學

選擇題 (0)

申論題 (14)

(1)wSigma-Minusmethod作圖时的y軸、斜率和截距(5分)

(2)以 Excretion Rate Method 作圖時的y軸、斜率和距·(5分)

(1)V_D的定義及代表的意義。(5分)

(2)寫出V_D與蛋白结合之關係式子(所有參數及符號須清楚標註其名稱)(5分)

(3)延續(2)，寫出上述關係式子之推導步驟。(5分)

(1)寫出藥品的四大分類(8分)

(2)對各類藥品的體內吸收分別提出改善方法(8分)

(1)若採用人體血液及尿液檢品,寫出最常被用於評估的藥動參數各2個。(4分)

(2)一般被用於評估生體相等性的2種统計方法及判定原則。(5分)

5. Phenytoin is an anticonvulsant agent with low extraction ratio and nonlinear pharmacokinetic properties. Phenytoin is mainly metabolized by CYP2C9 and partly by CYP2C 19. Phenytoin is also known to be a substrate of P-glycoprotein. Following an oral administration, picase describe how genetic polymorphism may influence the pharmacokinetic properties (in terms of clearance, AUC, and brain distribution) of phenytoin and clinical outcome of epileptic treatment. (20 points; 5 points each)

6. Phenytoin was administered to a patient at dosing rates of 150 and 300 mg day, respectively. The steady-state plasma drug concentrations were 8.6 and 25.1 mg/L. respectively. What is the dose needed to achieve a steady-state concentration of 11.3 mg/L?(必須列解題過程)(10points)

7. Why does a drug that has a high extraction ratio (e.g., propranolol) demonstrate greater differences between individuals after oral administration than afier intravenous administration? (5 points)

8. The risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent therapy with erythromycin, cyclosporine. or fibrate. Pravastatin (F = 0.17) is HMG-CoA reductase inhibitor and is a substrate of OATPI B1. Explain the impacts of the changes in the OATP I BI activity on the therapeutic efficacy and myopathy of pravastatin. respectively.(5 points)

9. The AUC and AUMC values of drug-A following an I. V. bolus of 5 mg are 278 ug-hr²/L, and 1 390 pg-hr?/L, respectively. The plasma concentration profile of this drug can be described by one-compartment model. Calculate the volume of distribution at steady-state (Vdss) of this drug (10 points)